Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered ...
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
By holding onto shares of fantastic companies for years or decades, and adding to your positions when you have more capital ...
Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
clinicaltrialsarena6d
Moderna blamed after children offered £1,500 to take part in Covid-19 trial
An NHS paediatrician sent a WhatsApp message offering children and parents £1,500 to take part in Moderna’s Phase III ...
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
PMLiVE6d
Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis
Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...
Eli Lilly’s EBGLYSS offers long-term disease control in atopic dermatitis trial
Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
Medindia6d
FDA Approves EBGLYSS Drug for Atopic Dermatitis in Adults and Children
EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...